Decheng Capital LLC Cuts Stock Holdings in Upstream Bio, Inc. $UPB

Decheng Capital LLC decreased its stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) by 13.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,724,868 shares of the company’s stock after selling 418,210 shares during the period. Upstream Bio makes up 3.7% of Decheng Capital LLC’s portfolio, making the stock its 3rd biggest position. Decheng Capital LLC owned about 0.05% of Upstream Bio worth $24,524,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in UPB. GF Fund Management CO. LTD. bought a new position in shares of Upstream Bio in the fourth quarter valued at approximately $29,000. Torren Management LLC bought a new stake in Upstream Bio during the fourth quarter worth approximately $30,000. BNP Paribas Financial Markets raised its holdings in Upstream Bio by 229.8% during the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock worth $34,000 after purchasing an additional 2,158 shares in the last quarter. Legal & General Group Plc lifted its position in Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the period. Finally, Empowered Funds LLC acquired a new stake in Upstream Bio in the fourth quarter worth approximately $45,000.

Analyst Upgrades and Downgrades

UPB has been the subject of a number of research reports. HC Wainwright started coverage on Upstream Bio in a research note on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price target for the company. JPMorgan Chase & Co. downgraded Upstream Bio from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $35.00 to $8.00 in a research note on Friday, June 12th. Mizuho cut their price objective on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, May 14th. Evercore cut Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 target price for the company. in a research note on Friday, March 27th. Finally, Wall Street Zen lowered shares of Upstream Bio from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $33.17.

Upstream Bio Stock Performance

NASDAQ UPB opened at $6.59 on Thursday. Upstream Bio, Inc. has a 1 year low of $5.85 and a 1 year high of $33.68. The business’s fifty day moving average is $7.29 and its two-hundred day moving average is $12.53. The stock has a market capitalization of $358.63 million, a P/E ratio of -2.26 and a beta of 1.23.

Upstream Bio (NASDAQ:UPB) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.02). The company had revenue of $1.03 million for the quarter, compared to the consensus estimate of $1.03 million. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%. On average, research analysts forecast that Upstream Bio, Inc. will post -2.9 earnings per share for the current year.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.